BR100 Increased By (0.43%)
BR30 Increased By (1.3%)
KSE100 Increased By (0.62%)
KSE30 Increased By (0.65%)
BECO 5.42 Decreased By ▼ -0.07 (-1.28%)
BML 56.00 Decreased By ▼ -0.76 (-1.34%)
BOP 35.22 Increased By ▲ 0.10 (0.28%)
CNERGY 8.17 Increased By ▲ 0.02 (0.25%)
DCL 11.55 Increased By ▲ 0.04 (0.35%)
FCCL 57.60 Increased By ▲ 0.85 (1.5%)
FCSC 5.16 Increased By ▲ 0.01 (0.19%)
FFL 17.97 Increased By ▲ 0.09 (0.5%)
FNEL 1.25 No Change ▼ 0.00 (0%)
HUMNL 11.08 Decreased By ▼ -0.04 (-0.36%)
KEL 8.63 Increased By ▲ 0.21 (2.49%)
KOSM 6.66 Increased By ▲ 0.08 (1.22%)
MLCF 105.70 Increased By ▲ 2.40 (2.32%)
NBP 200.61 Increased By ▲ 0.43 (0.21%)
PACE 11.44 Increased By ▲ 0.15 (1.33%)
PAEL 44.75 Increased By ▲ 1.28 (2.94%)
PIAHCLA 28.48 Increased By ▲ 0.99 (3.6%)
PIBTL 18.82 Increased By ▲ 1.12 (6.33%)
PPL 245.50 Increased By ▲ 1.18 (0.48%)
PRL 35.32 Decreased By ▼ -0.11 (-0.31%)
PTC 65.81 Increased By ▲ 0.46 (0.7%)
SEARL 95.10 Increased By ▲ 1.78 (1.91%)
SSGC 31.96 Decreased By ▼ -0.98 (-2.98%)
TELE 8.88 Decreased By ▼ -0.03 (-0.34%)
THCCL 66.99 Increased By ▲ 0.27 (0.4%)
TPLP 10.89 Increased By ▲ 0.06 (0.55%)
TREET 25.25 Increased By ▲ 0.13 (0.52%)
TRG 65.66 Increased By ▲ 0.76 (1.17%)
WAVES 10.90 Decreased By ▼ -0.03 (-0.27%)
WTL 1.27 Increased By ▲ 0.02 (1.6%)
Business & Finance

Pakistani pharma announces to ensure availability of Sputnik V vaccine

  • The Drug Regulatory Authority of Pakistan (DRAP) on February 1st 2021 granted Emergency Use Authorisation (EUA) for ‘Gam-Covid-Vac’ combined vector vaccine to prevent coronavirus infection caused by SARS CoV-2 virus.
Published February 2, 2021 Updated February 2, 2021 02:20pm

AGP Limited, the Pakistani pharmaceutical company authorised to import and introduce the ‘Sputnik V’ vaccine in Pakistan has said that it is now making efforts to ensure the availability of sufficient supplies of vaccine on an emergency basis.

The Drug Regulatory Authority of Pakistan (DRAP) on February 1st 2021 granted Emergency Use Authorisation (EUA) for ‘Gam-Covid-Vac’ combined vector vaccine to prevent coronavirus infection caused by SARS CoV-2 virus.

The vaccine has been developed by the Gamaleya National Centre of Epidemiology and Microbiology, Russia one of the world's leading research institutions. This vaccine has been approved by 15 countries including Russia, Hungary, Argentina and the United Arab Emirates with registrations underway in several other countries.

“As per the Interim Clinical Study Report which is based on the Phase III trials of 21,862 volunteers the efficacy of Sputnik V has been determined at 91.6% with 100% efficacy against severe cases of COVID-19. The vaccine has a good safety profile and in particular there are no strong allergy is caused by the vaccine,” stated the pharma.

“This is by far the most effective COVID-19 vaccine to have received EUA in Pakistan and can be administered two persons aged 18 and above including persons aged above 60,” it added.

Comments

Comments are closed for this article.